Rise In Gene Therapy Driving The Growth Of The Market Due To Advancements In Genetic Engineering: Strengthening the Growth Trajectory of the Familial Mediterranean Fever Pharmaceuticals Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Familial Mediterranean Fever Pharmaceuticals Market Through 2025?
The market for pharmaceuticals treating familial mediterranean fever has seen substantial growth in the past few years. The market's valuation is estimated to increase from $1.64 billion in 2024 to $1.72 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.1%. This increase during the historical period is due to factors such as the growing prevalence of the disease, an increase in migration and the aging population, a surge in incidents of genetic anomalies within the MEFV gene, along with an increase in genetic mutation.

What's the Projected Size of the Global Familial Mediterranean Fever Pharmaceuticals Market by 2029?
The market of pharmaceuticals for familial Mediterranean fever is projected to experience vigorous growth in the coming years, reaching a size of $2.1 billion in 2029, with a compound annual growth rate (CAGR) of 5.1%. This growth during the anticipated period can be ascribed to the increasing adoption of cutting-edge cancer treatments, escalating interest in gene and biological therapies, rising utilization of advanced therapy, expanding use of effective drugs, and broad-scale adoption of supportive therapies. Notable trends in the predicted period encompass progress in treatment methods, the debut of new drug categories, cooperation among academic establishments, research entities, and pharmaceutical firms, the adoption of novel therapeutics, and advancements in technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/familial-mediterranean-fever-pharmaceuticals-global-market-report

Top Growth Drivers in the Familial Mediterranean Fever Pharmaceuticals Industry: What's Accelerating the Market?
The boom in gene therapy is projected to fuel the expansion of the familial Mediterranean fever (FMF) pharmaceuticals market in the future. Gene therapy, a medical intervention that alters or substitutes defective genes to ward off or treat diseases at the genetic scale, is on the rise due to progress in genetic engineering. This progress allows for accurate targeting and correction of genetic disorders, providing possible solutions for diseases that were previously incurable. Gene therapy has a positive effect on familial mediterranean fever (FMF) pharmaceuticals by specifically targeting the underlying mutations in the MEFV (Mediterranean fever) gene, potentially providing a lasting or even permanent cure as opposed to just managing the symptoms. For example, in July 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit organization, reported that 76 gene therapy trials had begun in the second quarter of 2024, a 25% surge from the previous quarter. As such, the burgeoning field of gene therapy is propelling the growth of the familial Mediterranean fever (FMF) pharmaceuticals market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23397&type=smp

What Trends Will Shape the Familial Mediterranean Fever Pharmaceuticals Market Through 2029 and Beyond?
Key players in the familial mediterranean fever (FMF) pharmaceuticals market are prioritizing the development of sophisticated treatments, such as economically viable generic options, for the purpose of exploring new biologics and gene therapies. An affordable generic alternative is essentially a less expensive version of a name-brand drug but maintains the same active components, dosage guidelines, safety measures, and efficacy. For example, Camber Pharmaceuticals Inc., a pharmaceutical manufacturer based in the US, made a significant move in January 2022 by launching generic versions of Colcrys (colchicine) tablets, thereby broadening its product range. These tablets serve the purpose of treating and preventing familial mediterranean fever (FMF) in adults and children who are at least four years old, in addition to managing gout flare-ups. They are available in 0.6 mg strength, packaged in bottles that contain 30 and 100 units. This initiative underscores Camber's dedication to providing high-caliber, cost-effective generic medicines as part of their commitment to improving patient care.

What Are the Main Segments in the Familial Mediterranean Fever Pharmaceuticals Market?
The familial mediterranean fever pharmaceuticals market covered in this report is segmented -

1) By Drug Type: Colchicine, Interleukin-1 Inhibitors, Anti-IL-6 Drugs
2) By Route Of Administration: Oral, Injectable
3) By End Users: Hospitals, Clinical Diagnostic Laboratories, Other End Users

Subsegments:
1) By Colchicine: Oral Colchicine, Intravenous Colchicine
2) By Interleukin-1 Inhibitors: Anakinra, Canakinumab, Rilonacept
3) By Anti-IL-6 Drugs: Tocilizumab, Sarilumab, Siltuximab

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23397&type=smp

Which Top Companies are Driving Growth in the Familial Mediterranean Fever Pharmaceuticals Market?
Major companies operating in the familial mediterranean fever pharmaceuticals market are Merck & Co. Inc., Bristol Myers Squibb, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Swedish Orphan Biovitrum AB (Sobi), Granules Pharmaceuticals Inc., Sanmar Group, Indena S.p.A., Harman Finochem, Camber Pharmaceuticals Inc., R-Pharm Group, Alchem International, AdvaCare Pharma USA LLC, ViennaLab Diagnostics GmbH, Honour Lab Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma

Which Regions Will Dominate the Familial Mediterranean Fever Pharmaceuticals Market Through 2029?
Middle East was the largest region in the familial mediterranean fever pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial mediterranean fever pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23397

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.